Barclays PLC Beam Therapeutics Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 183,214 shares of BEAM stock, worth $5.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

183,214

Previous 183,214 -0.0%

Holding current value

$5.32 Million

Previous $4.49 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$22.57 - $33.14 $2.29 Million - $3.36 Million	101,387 Added 123.9%	183,214 $4.49 Million
Q2 2024 Aug 14, 2024	SELL	$21.22 - $32.66 $102,895 - $158,368	-4,849 Reduced 5.59%	81,827 $1.92 Million
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $3.79 Million - $7.29 Million	-161,708 Reduced 65.1%	86,676 $2.86 Million
Q4 2023 Feb 15, 2024	BUY	$17.69 - $30.76 $897,537 - $1.56 Million	50,737 Added 25.67%	248,384 $6.76 Million
Q3 2023 Nov 07, 2023	BUY	$23.01 - $32.46 $1.22 Million - $1.72 Million	53,115 Added 36.75%	197,647 $4.75 Million
Q2 2023 Aug 03, 2023	BUY	$29.32 - $35.99 $847,435 - $1.04 Million	28,903 Added 25.0%	144,532 $4.62 Million
Q1 2023 May 04, 2023	SELL	$30.15 - $48.79 $180,598 - $292,252	-5,990 Reduced 4.93%	115,629 $3.54 Million
Q4 2022 Feb 13, 2023	BUY	$36.73 - $51.6 $473,192 - $664,762	12,883 Added 11.85%	121,619 $4.76 Million
Q3 2022 Nov 03, 2022	BUY	$39.79 - $70.31 $3.11 Million - $5.5 Million	78,267 Added 256.87%	108,736 $5.18 Million
Q2 2022 Aug 12, 2022	BUY	$29.86 - $62.36 $461,157 - $963,087	15,444 Added 102.79%	30,469 $1.18 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $807,293 - $1.23 Million	15,025 New	15,025 $859,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.04B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account